ShareThis Page

Drug maker sued over contaminated laxative slapped with new FDA warning

Ben Schmitt
| Thursday, Nov. 2, 2017, 11:51 a.m.
Photos in the Singleton home in Hampton.
Ben Schmitt
Photos in the Singleton home in Hampton.
The Singletons on Thanksgiving Day 2015 in their Hampton home with twins Ariana, left, and Alivia. Alivia was  home for five weeks of her 9 months alive. She died May 4, 2016.
Supplied
The Singletons on Thanksgiving Day 2015 in their Hampton home with twins Ariana, left, and Alivia. Alivia was home for five weeks of her 9 months alive. She died May 4, 2016.

A Florida drug manufacturer at the center of a wrongful death lawsuit involving the parents of a Hampton infant is under fire again by the Food and Drug Administration.

PharmaTech LLC of Davie, Fla., is being sued in federal court in Pittsburgh by Jocelyn and Lamont Singleton in connection with the May 4, 2016, death of their daughter, Alivia Singleton, who was three months shy of her first birthday.

The lawsuit contends Alivia contracted a bacterial infection after being given a liquid laxative, while hospitalized, made by PharmaTech. The laxative, known as “Diocto Liquid,” was contaminated with Burkholderia cepacia, a rare form of bacteria, according to the lawsuit.

On Friday, the FDA issued an advisory regarding PharmaTech products after a multistate outbreak of Burkholderia cepacia bacterial infections traced to liquid drug products. The infections afflicted at least eight patients in California and Maryland, the FDA said in a news release.

“FDA reminds health care professionals and patients not to use any liquid product manufactured by PharmaTech's Davie, Florida, facility,” the news release said.

PharmaTech vacated its Davie building in June, a town spokesman told the Tribune-Review this week. Its website is down and a former phone number is disconnected.

In June 2016, a month after Alivia died, the FDA and the Centers for Disease Control and Prevention reported an investigation of multistate outbreaks of Burkholderia cepacia, or B. cepacia infections.

A month later, PharmaTech voluntarily recalled all of its Dicoto Liquid products. The FDA confirmed the laxative was contaminated with B. cepacia linked to infections in five states, including Pennsylvania.

PharmaTech contends that the Pittsburgh lawsuit should be dismissed because it “lacks specificity.”

Attorney Brendan Lupetin, who represents the Singleton family, said his claims are legitimate.

Ben Schmitt is a Tribune-Review staff writer.

TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.